Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
126. |
ECCT/22/03/10 | Solidarity Trial Vaccines Solidarity Trial Vaccines: An international randomised trial of candidate vaccines against COVID-19 |
Principal Investigator(s) 1. Ayallo, John Mark O, AYALLO 2. Prof KAWANGO AGOT AGOT 3. DR. LUCAS TINA OTIENO OTIENO 4. DR.MARICIANA ONONO ONONO 5. DR.JANET OYIEKO OYIEKO 6. DR.Fredrick Kipyego Sawe SAWE 7. DR. MICHAEL M MUTUA Mutua 8. Dr Joshua Kimani KIMANI 9. DR. IRENE A. MUGENYA MUGENYA Site(s) in Kenya 1. SWOP (Nairobi City county) 2. K-IRDO –KISUMU (Kisumu county) 3. VIBRI- VICTORIA BIOMEDICAL RESEARCH INSTITUTE –KISUMU (Kisumu county) 4. KEMRI-CENTRE FOR MICROBIOLOGY RESEARCH (CMR) LUMUMBA –KISUMU (Kisumu county) 5. KEMRI –CENTRE FOR CLINICAL RESEARCH BUTERE(CCR) (Kakamega county) 6. Kenya Medical Research Institute/Walter Reed Project (KEMRI/WRP) (Kericho county) 7. UNIVERSITY OF NAIROBI- KAVI- KANGEMI (Nairobi City county) 8. UNIVERSITY OF NAIROBI- KAVI- KNH (Nairobi City county) |
View |
127. |
ECCT/22/03/09 | GBT 132-Inclacumub PH3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Videlis N Nduba 2. Bernhards Ragama Ogutu 3. Fredrick Asirwa Chite Site(s) in Kenya 1. KEMRI Siaya Clinical Research Annex (Siaya county) 2. KEMRI/CRDR (Nairobi City county) 3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county) 4. Strathmore University Medical Centre (Nairobi City county) |
View |
128. |
ECCT/22/03/08 | CVIA 092 “ A Phase 3 Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Safety (Ages 6 Months to 45 Years) and Non-inferiority (Ages 9-12 Months) of Multi-dose and Single-dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) against Typbar TCV® and Lot-to-Lot Consistency of the Immune Response (Ages 9-12 Months) to Multi-dose Vial Formulation EuTCV in Healthy African Participants”. |
Principal Investigator(s) 1. Dr Lucy Koech Chepkurui Koech Site(s) in Kenya KEMRI/ KERICHO CRC |
View |
129. |
ECCT/22/03/07 | ELEVATUM A PHASE IIIB/IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE FARICIMAB (RO6867461) TREATMENT RESPONSE IN TREATMENT-NAÏVE, UNDERREPRESENTED PATIENTS WITH DIABETIC MACULAR EDEMA |
Principal Investigator(s) 1. Dr. Oscar Muwale Onyango 2. Dr. Muchai Gachago Site(s) in Kenya 1. The Nairobi Hospital (Nairobi City county) 2. City Eye Hospital (Nairobi City county) |
View |
130. |
ECCT/22/03/06 | Sickle Cell Disease A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Janet Oyieko 2. Fredrick Chite Asirwa 3. Bernhards Ogutu Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research institute (Kisumu county) 3. International Cancer Centre (Uasin Gishu county) 4. CREATES - Strathmore University Medical Centre (Nairobi City county) |
View |